Saint Affrique

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, primarily affecting older individuals with a median age of around 71 to 73 years. While treatment options like chemo-immunotherapies and targeted therapies exist, quality of life (QoL) in patients, especially those treated with acalabrutinib, remains underexplored in real-world settings. This research aims to describe the QoL of CLL patients treated with acalabrutinib from the start of treatment and over the following twelve months, using data from the national PLATON cohort in France. The study focuses on patients who began acalabrutinib therapy, either as monotherapy or combined with obinutuzumab, in routine care settings. It retrospectively analyzes data collected quarterly up to one year after treatment initiation. No additional visits or procedures are required, as the study uses existing patient information recorded in the PLATON database. Treatment details, patient demographics, disease status, and symptom evolution will all be examined to understand patient experience under real-life conditions. Participants' quality of life will be assessed using standardized questionnaires including the EORTC QLQ-C30 and the QLQ-CLL17 at treatment initiation and at 3, 6, 9, and 12 months thereafter. Treatment adherence will be monitored using the GIRERD questionnaire. Data quality is ensured through rigorous checks and monitoring. The main outcome is the QoL score changes over time, alongside secondary analyses of symptoms, treatment patterns, and patient support programs. Up to 120 patients will be included, with follow-up lasting 12 months from acalabrutinib initiation.